Retrospective study of the efficacy and toxicity of lobaplatin‐etoposide chemotherapy in small cell lung cancer

BACKGROUND: A retrospective study was conducted to assess the efficacy and toxicity of lobaplatin‐etoposide (EL) chemotherapy for small cell lung cancer (SCLC). METHODS: The clinical data of 50 patients treated in our department from May 2014 to March 2018 were obtained. Untreated patients with SCLC administered LBP intravenously (IV) at 30 mg/m(2) on day 1 and etoposide IV at 100 mg/m(2) on days 1, 2, and 3 were enrolled. The treatment was cycled every 21 days. RESULTS: The median overall and progression‐free survival rates of the 50 patients were 11.67 (range: 7.30–16.04) and 6.8 (range: 5.25–8.35) months, respectively, with an overall response rate of 66% and a disease control rate of 90%. The most frequent drug‐related adverse effects were leukopenia and neutropenia, and no grade 3/4 hepatotoxicity or nephrotoxicity was observed. CONCLUSION: These results indicate that LBP‐containing chemotherapy is effective and tolerable for SCLC in terms of response and survival.